The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma

Annals of Hematology

Volumn 92, Issue 1, 2013, Pages 97-100

  Puig, Noemí ^a   Sarasquete, María E ^a,b   Alcoceba, Miguel ^a,b   Balanzategui, Ana ^a   Chillón, María C ^a,b   Sebastián, Elena ^a   Marín, Luis A ^a,b   Díaz, Marcos González ^a,b   San Miguel, Jesús F ^a,b   Sanz, Ramón García ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

Author keywords

Applicability; CD138+ selection; Minimal residual disease; Multiple myeloma; Real time quantitative PCR (RQ PCR)

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; SYNDECAN 1;

ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DJH GENE; DNA SEQUENCE; GENE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN HEAVY CHAIN GENE; KDE GENE; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VDJH GENE;

BONE MARROW; BONE MARROW EXAMINATION; CELL SEPARATION; CLONE CELLS; DNA, NEOPLASM; GENE REARRANGEMENT, B-LYMPHOCYTE; HUMANS; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM, RESIDUAL; REAL-TIME POLYMERASE CHAIN REACTION; SYNDECAN-1; V(D)J RECOMBINATION;

EID: 84872312930     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1566-3     Document Type: Article

References (8)

1. Chanan-Khan AA, Giralt S (2010) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28:2612-2624
2. Rajkumar SV, Harousseau JL, Durie B, Anderson KC et al (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117(18):4691-4695
3. Paiva B, Vidriales MB, Cerveró J, Mateo G et al (2008) Multiparameter flow cytometry is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017-40213
4. Martínez-Sánchez P, Montejano L, Sarasquete ME, García-Sanz R et al (2008) Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-PCR: the prognostic impact of achieving molecular response. Br J Haematol 142:766-774
5. Sarasquete ME, García-Sanz R, González D, Martínez J et al (2005) Minimal residual disease monitoring in multiple myeloma: a comparison between allelic specific real-time oligonucleotide polymerase quantitative and flow cytometry. Haematologica 90:1365-1372
6. Ladetto M, Pagliano A, Ferrero S, Cavallo F et al (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28(12):2077-2084
7. van Dongen JJM, Langerak AW, Brüggemann M, Evans PAS et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317
8. Martinelli G, Terragna C, Zamagni E, Ronconi S et al (2000) Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 18(11):2273-2281